Litcius/Paper detail

LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)

Yoshiro Nakahara, Terufumi Kato, Reiko Isomura, Toshihiro Misumi, Motohiro Tamiya, Kiyotaka Yoh, Naoki Furuya, Akira Ono, Yuichi Takiguchi, K. Koyama, Satoshi Ikeda, Kageaki Watanabe, Takaaki Tokito, Narihito Seki, Hisao Imai, Takehito Shukuya, Yuji Shibata, Shinobu Hosokawa, Toshiyuki Kozuki, Hiroaki Okamoto

2023Annals of Oncology14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOsimertinibRamucirumabInternal medicineOncologyNeutropenianon-small cell lung cancer (NSCLC)Clinical endpointLung cancerHazard ratioT790MPneumonitisChemotherapyRandomized controlled trialCancerLungErlotinibConfidence intervalGefitinibEpidermal growth factor receptorA549 cellLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Diagnosis and Treatment
LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833) | Litcius